What Инфакол Treats: Main Uses and Benefits

Инфакол is commonly used to address the physical manifestations of excessive gastrointestinal gas. It is relevant for easing symptoms related to physical discomfort, such as the acute, painful pressure associated with flatulence and bloating, and the persistent sensation of abdominal fullness. This medication is generally considered relevant for managing symptom clusters that create noticeable physiological strain, particularly in its primary audience, infants and newborns. It is applied in clinical settings involving acute or unstable symptom patterns, such as post-feeding distress linked to air swallowing. This supportive relief contributes to easing the overall symptom burden and supports general well-being during symptomatic periods. “It is commonly used across conditions presenting with acute episodes and relevant in situations requiring short-term symptomatic support.” Applicable in situations marked by recurrent or episodic manifestations of gas retention, it offers support that helps patients cope more steadily with symptom fluctuations.

---

Quick Fact: Relief for Acute Gas Symptoms

Property	Therapeutic Scope
Primary Focus	Excessive gastrointestinal gas and flatulence
Symptom Types	Painful pressure, tightness, bloating, and fullness
Target Group	Infants and newborns (gas-related distress)
Benefit Frame	Contributes to easing overall symptom burden

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility Map: Who can and cannot use Инфакол

The eligibility profile for Инфакол (Simethicone oral suspension) is determined by its specific formulation and non-systemic nature. Official regulatory documents establish that this product is intended for and approved for use in the infant and newborn population, starting from birth onwards.

---

Contraindications and Restrictions

Category	Regulatory Status
Absolute Prohibition	Contraindicated in patients with known or suspected hypersensitivity to Simethicone or any other ingredient, including excipients like methyl and propyl hydroxybenzoates.
Age-Group Exclusion	Use in adults and the elderly is typically specified as not applicable for this specific infant drop formulation.
Conditional Use	Use in infants being treated for a thyroid disorder (e.g., with Levothyroxine) is restricted due to the potential for Simethicone to impair the absorption of the thyroid medication.
Pregnancy/Lactation	This status is often labeled as not applicable given the product's primary pediatric indication. The active ingredient, Simethicone, is generally not absorbed systemically.

---

Official labeling defines that the medicine must not be used by individuals with hypersensitivity to its components. Furthermore, eligibility is constrained by a specific regulatory warning against concurrent use in infants receiving Levothyroxine therapy.

Interactions with other medicines and products — official regulatory information for Инфакол

Инфакол (Simethicone) is classified as a medicine with a highly limited systemic interaction profile. Due to its non-systemic activity, the active ingredient is not absorbed into the bloodstream, which means official regulatory documents list no metabolic interactions (e.g., involving CYP enzymes) or transporter-mediated interactions.

---

Pharmacokinetic Interactions and Timing Restrictions

Category	Official Regulatory Documentation
Specific interacting medicines	Levothyroxine (thyroid replacement products).
Mechanistic basis	Reduction of oral absorption due to local physical binding or adsorption within the gastrointestinal tract.
Formal outcome	Decreased systemic exposure of Levothyroxine.

---

Administration Separation Requirement

The primary interaction formally documented in official prescribing information is with Levothyroxine. Co-administration may lead to reduced oral absorption of the thyroid hormone, consequently lowering its therapeutic exposure.

To manage this interaction, regulatory labels mandate a timing-based separation. Administration of Simethicone must occur at least 4 hours before or after the dose of Levothyroxine to mitigate the potential for reduced absorption.

No contraindicated combinations or interactions with food, alcohol, or herbal products are explicitly specified in official regulatory sources for Simethicone as a single-ingredient product.

The compound Simethicone operates exclusively via a non-systemic, physical mechanism localized to the gastrointestinal lumen, without affecting any biological receptors, enzymes, or metabolic pathways.

Physical Surface Tension Modulation

The compound's primary action is to act as a surface-active polymer, specifically targeting the surface tension of the small, stable gas bubbles trapped in the intestinal contents and mucus. By reducing this surface tension, the compound physically destabilizes the bubble walls, which initiates the crucial step of gas coalescence.

---

Modulation of Gas State and Transit

The process of coalescence merges numerous small, foam-like bubbles into fewer, larger gas masses. These larger gas masses exhibit increased susceptibility to the body's natural peristaltic movements, which facilitates their movement through the gut and expulsion. This physical change contributes to the modulation of intraluminal pressure by altering the physical state of the gas responsible for localized distension within the gastrointestinal tract.

Administration Scope and Official Dosing

The administration of Инфакол (Simethicone oral suspension) is intended exclusively for the oral route as a liquid drop formulation. Dosing is determined by the patient's age and weight, distinguishing between two primary groups. Infants under two years of age (or under 24 lbs) are administered a volume of 0.3 mL, which delivers 20 mg of Simethicone. For children two years of age and older (or over 24 lbs), the dose is 0.6 mL (40 mg).

---

Frequency and Procedural Requirements

Usage is governed by an as-needed (PRN) frequency pattern, typically coinciding with feeding schedules, such as after meals and at bedtime. This flexible schedule is governed by a maximum limit; instructions specify that administration must not exceed 12 doses within a 24-hour period. Proper preparation requires the container to be shaken well before use to ensure the uniformity of the suspension. For accurate measurement, it is required to use only the enclosed dropper or syringe. The dose may be administered directly or mixed with water, infant formula, or other suitable liquids.

---

Official Administration Protocol

Connection to the overall use protocol: Standard instructions define a non-systemic, episodic usage protocol that relies on oral administration of a carefully measured suspension. The liquid preparation must be homogenized by shaking, and the correct volume must be administered using the designated measuring tool. This structured protocol ensures a standardized pattern of use.

Research Evidence / Overview of Studies for Инфакол

This section summarizes the published research regarding the use of Инфакол (Simethicone) for infant colic. The purpose is to describe the types of studies that exist, the outcomes they measured, and what the available evidence suggests, using cautious language that reflects the degree of scientific uncertainty.

---

Evidence Overview for Symptomatic Relief of Infant Colic

Research exploring the effects of Инфакол for infant colic involves several Randomized Controlled Trials (RCTs) and subsequent analyses that combine the findings of multiple studies, known as systematic reviews. These studies were applied in research contexts involving fluctuating or unstable symptoms, where they were used in research exploring how symptoms change over time.

Researchers typically focus on outcomes related to physical discomfort and daily functioning or activity level. The main outcome measured relates to the intensity or variability of symptoms, such as change in an infant's daily crying time (often recorded in minutes by parents over a defined time interval). The study designs included monitoring for any side effects or events.

What the studies reported: Studies report how symptoms evolved in the observed populations, and findings were mixed. Some early trials described patterns observed in the studies, including measurements of outcomes in both the simethicone and placebo groups. However, systematic reviews, which evaluate the broader evidence landscape by pooling data from multiple RCTs, generally reported that measurements of average daily crying time for infants receiving simethicone do not show patterns that differentiate from the placebo group. Overall, this research contributes to understanding symptom patterns, but multiple comprehensive reviews have described the evidence for simethicone as low to moderate quality, with findings often indicating that study outcomes were inconclusive or not distinct from placebo.

---

Comparing Инфакол Against Placebo or Other Treatments

Key research scenarios include studies that directly compared Инфакол (or similar simethicone formulations) against a placebo (an inactive substance). These studies are designed as double-blind trials, meaning neither the parents nor the researchers knew which substance was being administered.

In one large, randomized, placebo-controlled, multicenter trial, researchers monitored responses over defined time intervals. The research described patterns where measurements of outcomes were similar when comparing simethicone to a placebo. Researchers examined whether observed changes may be influenced by factors such as the natural resolution of the condition or the high placebo response rate typically observed. The research provides context but not individual predictions of response. Research also examined simethicone in comparison to other therapeutic approaches. These findings were mixed, and comparative evidence is lacking or inconclusive.

---

Long-Term Studies and Follow-Up

The majority of research on Инфакол and infant colic focuses on research exploring short-term symptom changes and temporary physiological imbalance. These trials typically observed responses over defined time intervals, often lasting only one to four weeks.

As a result, there is limited information for long-term outcomes related to this treatment. Long-term effects are not fully established, and there are few data available that characterize the sustained effect, if any, after the treatment is stopped. Research does not determine whether an individual will respond similarly over an extended period, and the follow-up durations were limited.

---

Evidence in Specific Infant Populations

The populations evaluated in the core RCTs were infants diagnosed with colic, typically between the ages of one week and six months. The results apply only to the populations studied under the conditions of the trials.

Data for certain groups, such as very young infants (e.g., premature babies) or those with underlying complex medical issues (comorbidities), remain insufficient. The sample sizes were modest in many studies, meaning that the research has limited capacity to draw conclusions about specific subgroups of infants who may experience different degrees of symptom intensity or variability. Comparative evidence for these specialized populations is lacking.

---

What is Still Uncertain About the Research for Инфакол

Research highlights what is known—and what is still uncertain. The primary uncertainty lies in the consistency of the findings, as the evidence quality varies across studies, and many systematic reviews report that the certainty remains low regarding the effectiveness compared to placebo.

Key limitations in the research include:

• Evidence Quality: The overall certainty remains low due to methodological differences and modest sample sizes across the available trials.
• Placebo Effect: The high rate of perceived improvement observed in infants receiving a placebo makes it difficult to definitively isolate any specific pattern associated with the product itself.
• Long-Term Data: Long-term effects are not well characterized, as follow-up durations were limited in the primary research.

Findings describe group patterns, not personal outcomes, and the evidence contributes to the broader landscape of understanding conditions characterized by fluctuating or episodic manifestations.

Key Studies & References

1. A double-blind, randomized, placebo-controlled, multi-center study of Simethicone in the treatment of infant colic

Common questions about Инфакол (FAQ)

---

Q: Через сколько времени начинает действовать Инфакол?

A: Simethicone, the active ingredient, works locally in the digestive tract through a physical action, reducing the surface tension of gas bubbles. Because it is not systemically absorbed, it works by targeting the gas locally in the gut, with its action beginning shortly after administration. Official labeling advises using the designated measuring tool to ensure the correct volume is administered.

---

Q: Можно ли давать Инфакол ребенку с искусственным вскармливанием?

A: Yes, official administration instructions state that the dose may be mixed with suitable liquids, including water and infant formula. Regulatory documents specify that the measured volume should be administered using the designated measuring device.

---

Q: Инфакол вызывает сонливость у ребенка?

A: Official information indicates that Simethicone acts only locally within the gastrointestinal tract. Due to its non-systemic action, which means it is not absorbed into the bloodstream, Simethicone is generally not expected to affect the central nervous system or cause drowsiness.

---

Q: Нужен ли рецепт врача, чтобы купить Инфакол?

A: No. According to regulatory agencies, Simethicone products are classified as Over-The-Counter (OTC) drugs. This means the medicine is available for purchase without requiring a doctor’s prescription.

---

Q: Может ли Инфакол изменить цвет стула у младенца?

A: For standard Simethicone drops, changes in stool color are not typically listed as a known or common side effect in regulatory reports. However, some specialized Simethicone formulations used in medical imaging can temporarily cause feces to appear orange-colored until the product is fully eliminated.

---

Q: Что делать, если пропустил прием Инфакола?

A: Simethicone is typically taken only as needed when symptoms of gas or bloating occur. If the product is being administered on a regular schedule, official guidance usually advises skipping the missed dose and continuing with the regular schedule. Official guidance advises against taking a double dose to make up for a missed one.

---

Q: Инфакол содержит сахар или лактозу?

A: The specific inactive ingredients, including the presence of sugars (such as sucrose or dextrose) or lack of lactose, can vary widely by brand and exact formulation. As inactive ingredients vary by formulation, it is necessary to check the list of ingredients on the specific product label for the most accurate information on sweeteners and other components.

---

Q: Инфакол эффективен при вздутии живота у взрослых?

A: Simethicone, the active ingredient, is generally used to relieve symptoms of gas, such as uncomfortable pressure and bloating, in both adults and children. However, the specific Infacol drop formulation is primarily labeled and packaged for use in infants and younger children.

---

Q: Что входит в состав Инфакола кроме симетикона?

A: In addition to the active ingredient, Simethicone, the product contains various inactive ingredients (excipients). Examples often include preservatives like methyl and propyl hydroxybenzoates. The full list of excipients, which are inactive ingredients that may include flavorings or stabilizers, can be found on the specific product label.

---

Q: Инфакол подходит для недоношенных детей?

A: Simethicone is indicated for infants and newborns. While generally used in the pediatric population, official documents note that data from core clinical trials for certain subgroups, such as premature babies, may be insufficient. Consultation with a healthcare provider is generally recommended for use in specialized populations.

---

Q: Почему Инфакол пахнет или имеет определенный вкус?

A: The specific scent and flavor of the liquid product are determined by the inactive ingredients used in the formulation. These ingredients, such as flavorants, are added to make the suspension palatable and easier for infants to take.

---

Q: Может ли Инфакол помочь при срыгиваниях?

A: The medicine is classified as an anti-gas agent, and its formal indication is to relieve discomfort caused by trapped gas and bloating. It is not specifically indicated for the treatment of reflux or regurgitation, which are conditions involving the movement of stomach contents.

---

Q: Инфакол вызывает запор или понос?

A: Official reports document that minor gastrointestinal discomfort, including nausea and constipation, are potential adverse reactions, though their frequency is classified as uncommon or unknown. Diarrhea is not typically listed as a documented side effect for single-ingredient Simethicone.

---

Q: Почему Инфакол иногда советуют при подготовке к УЗИ?

A: Simethicone is used in specialized diagnostic settings to reduce gas shadowing in the gastrointestinal tract. This anti-foaming action improves the clarity of images during procedures like abdominal ultrasound, allowing for better visibility of internal anatomy.

---

Q: Какие бывают нежелательные реакции на Инфакол, кроме аллергии?

A: Besides hypersensitivity (allergic reactions), the officially documented non-allergic adverse reactions include minor gastrointestinal discomfort. These can include nausea and constipation, although the frequency of these events is generally uncommon or not known.

---

Q: В чем научное обоснование действия Инфакола?

A: The scientific justification is based on the compound's physical mechanism of action. Simethicone is a surface-active polymer that reduces the surface tension of small gas bubbles trapped in the gut, causing them to merge into larger bubbles. This coalescence facilitates the body's natural processes of gas movement and expulsion.

---

Q: Как быстро Инфакол снимает боль?

A: Simethicone works by rapidly changing the physical state of trapped gas, which eases the associated pressure and discomfort. While this physical change is fast, official labeling documents do not specify an exact timeframe for when relief will be experienced by an individual.

---

Q: Может ли Инфакол взаимодействовать с витаминами?

A: Simethicone’s known interaction is a localized effect that can reduce the absorption of the thyroid hormone Levothyroxine. There are generally no known interactions with most common vitamins. Regulatory guidance suggests informing a healthcare provider of all products being administered, including vitamins and supplements.

Storage and Disposal of Infacol

Official regulatory documents define specific conditions for storing and disposing of Infacol (Simethicone oral suspension) to ensure product integrity.

Condition Type	Requirement
Temperature	Store at a temperature not exceeding 25 C.
Handling	Must be stored protected from freezing.
Child Safety	Keep out of the sight and reach of children.
In-Use Stability	Discard any unused product 28 days after first opening the bottle.
Disposal	Dispose of unused or expired medicine in accordance with local requirements.

Medicines must not be disposed of via wastewater or standard household waste, as specified in the official labeling.